Pharmaceutical giant Novo Nordisk (NYSE: NVO) in 2024 launched a $4 billion expansion in Clayton that the Danish company says will create 1,000 new jobs ... Large NC shopping center sells for ...

STORY HIGHLIGHTS Novo Nordisk ... in the Town of Clayton to boost its manufacturing capacity for popular weight-loss drugs Wegovy and Ozempic. The investment will create 1,000 new jobs, the ...

In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...

Novo Nordisk has been repeatedly thrust into the limelight in recent weeks by Mr. Trump and his new administration. Robert F. Kennedy Jr., who has said he doesn’t like obesity drugs, is Mr ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Novo Nordisk’s medicines are now on the list of drugs subject to price negotiations. However, it’s unclear what will happen to this program in the future, especially under the new administration.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...